The patient underwent surgery, which confirmed a malignant neck paraganglioma with metastasis to a cervical lymph node. He had no family history of carotid body tumors or pheochromocytoma.

Vagal paragangliomas (VPs) are a rare subset of neuroendocrine tumour derived from paraganglia located in the head/neck that are usually indolent in nature. Typical clinical presentations include ...

A carotid body tumor (also known as a carotid body paraganglioma or a chemodectoma ... About 65 percent of all head and neck paragangliomas are carotid body tumors. The carotid body, which originates ...

the former model was diagnosed with multiple paraganglioma - a rare brain-skull tumor that was wrapping around her nerves and spreading through her neck. Vesce, who recently appeared on USA ...

The First International Symposium on Pheochromocytoma, held in October 2005, included discussions about developments concerning these rare catecholamine-producing tumors. Recommendations were made ...

Paraganglioma is a neuroendocrine tumour derived from extra-adrenal cells of the neural crest paraganglia of the autonomic nervous system. These rare neoplasms comprise of around 0.012% of head and ...

Patients (heterozygous for germline SDH mutations (subunits B, C or D) undergoing surgery for confirmed primary or metastatic PGL of abdomen, pelvis, mediastinum, neck or head. Tumor size should be ...

The Nucleic Acid Structure and Recognition Laboratory is interested in the peculiar genetics and biochemistry of paraganglioma (PGL), a human neuroendocrine tumor. A leading cause of this tumor ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

The panel of experts at the ISP felt strongly that localization of pheochromocytoma or paraganglioma ... abdomen and pelvis. If a tumor is not found, chest and neck images should be obtained ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.